| Identification | Back Directory | [Name]
N-((1S,3R)-3-(5-chloro-4-(1H-indol-3-yl)pyrimidin-2-ylamino)-1-methylcyclohexyl)-5-((E)-4-(dimethylamino)but-2-enamido)picolinamide | [CAS]
1816989-16-8 | [Synonyms]
SY-1365
Mevociclib
Mevociclib，SY-1365
SY-1365;SY 1365;SY1365
N-((1S,3R)-3-(5-chloro-4-(1H-indol-3-yl)pyrimidin-2-ylamino)-1-methylcyclohexyl)-5-((E)-4-(dimethylamino)but-2-enamido)picolinamide
N-[(1S,3R)-3-[[5-Chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-methylcyclohexyl]-5-[[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]amino]-2-pyridinecarboxamide
Inhibitor,triple negative breast cancer,TNBC,Mevociclib,Cyclin dependent kinase,SY1365,tumors,cancers,cell,inhibit,solid,CDK,small,SY 1365,CDK7/CycH/MAT1,lung
2-Pyridinecarboxamide, N-[(1S,3R)-3-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-methylcyclohexyl]-5-[[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]amino]- | [Molecular Formula]
C31H35ClN8O2 | [MOL File]
1816989-16-8.mol | [Molecular Weight]
587.11 |
| Chemical Properties | Back Directory | [density ]
1.34±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 125 mg/mL (212.90 mM) | [form ]
Solid | [pka]
12.04±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
N-[(1S,3R)-3-[[5-Chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-methylcyclohexyl]-5-[[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]amino]-2-pyridinecarboxamide is a CDK7 inhibitor and is used for anticancer treatments. | [in vivo]
Mevociclib (20mg/kg; i.v.; biw; for 35 days) inhibits tumor growth in TNBC in vivo models[2].
?
Mevociclib induces unique transcriptional signature[2].
| Animal Model: | Mice, HCC70 xenograft model[2] | | Dosage: | 20 mg/kg | | Administration: | Intravenous injection, twice weekly, for 35 days | | Result: | Inhibited tumor volume in vivo. |
| [IC 50]
CDK7 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|